The pharmaceutical company says it will continue to operate its production facility near Research Triangle Park.

North Carolina economic development officials have terminated an economic incentives agreement for Novartis Gene Therapies, ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...

Karen Hale, who joined Novartis in 2021 as chief legal officer, will take on the new chief legal and compliance officer role.

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation.